NCBiotech News

Seqirus, the world’s second largest influenza vaccine company, has broken ground for a $9 million expansion of its massive manufacturing facility in Holly Springs.

The North Carolina Biotechnology Center has announced the inaugural class of Pfizer-NCBiotech Distinguished Postdoctoral Fellows in Gene Therapy.

Locus Biosciences, born with the help of two loans from the North Carolina Biotechnology Center, has raised $19 million in Series A funding from major investors.

Pfizer, the global pharmaceutical giant, will expand its vaccine-manufacturing plant in Sanford with a $100 million investment in gene therapy that will add 40 jobs to its workforce.

Panaceutics, a personalized medicine and clinical nutrition company in Research Triangle Park, will partner with Florida Hospital’s Cardiovascular Institute on a new way to help patients with heart disease take all of their medicines as prescribed.

The billion-dollar cell culture Seqirus vaccine factory in Holly Springs has hit yet another milestone. The highly skilled workers at the sprawling factory southeast of Raleigh successfully produced the world’s first cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather than in eggs.

Achelios Therapeutics of Chapel Hill has completed a meeting with the U.S. Food and Drug Administration about a path to approval for its leading drug candidate, TOPOFEN, to treat acute and chronic migraine, a condition known for its debilitating pain.

A Virginia man has become the first person in the world to be treated for pancreatic cancer with a bio-absorbable, implantable radiation device called CivaSheet, developed by Durham-based CivaTech Oncology.

 

RTP's UVision 360 has been chosen by Medical Device and Diagnostic Industry (MD+DI), a print and online magazine, to participate in its annual Medtech Startup Showdown. North Carolina's life science and technology community can ensure one of our own makes it to Round 2 by voting now.

Heat Biologics, a Durham company developing immunotherapies to fight cancer, has reported positive results from a Phase 1b trial of its combination treatment for non-small cell lung cancer.

The Research Triangle Park-based personalized medicine and clinical nutrition company formerly known as Panacea BioMatx is quickly transforming itself in 2017.

When Heat Biologics licensed the immune system stimulating technology behind its ImPACT and ComPACT platforms from the University of Miami, it also licensed the tech behind Pelican Therapeutics Inc.

Wilmington physician Alan Brown, an impassioned inventor in his off hours, has transformed two of his ideas into award-winning product innovations – a self-illuminating speculum and a corneal marking system – designed to make eye surgeries more efficient and accurate, improving patient outcomes.

A group headlined by blazingly successful life science rainmaker Steve Butts, MBA, is hanging out a shingle in Morrisville, this time with $49 million in early funding support. They’re calling it Arrivo BioVentures.

Research Triangle Park startup CertiRx is teaming with a Croatian company, IN2trace Ltd., to combine its TraxSecur authentication technology with IN2trace’s CureCloud “serialization” technology into one software package, called TraxSecur Serialized Security.